Soluble mannose receptor as a predictor of prognosis of hepatitis B virus-related acute-on-chronic liver failure

Table 1 Demographic and clinical characteristics of the study subjects

Variable	HBV-ACLF (n = 43)	CHB (n = 43)	HCs (n = 20)
Age (yr)	42.65 ± 13.93	40.24 ± 14.41	41.00 ± 11.20
Male (%)	36 (83.7%)	35 (81.4%)	16 (80%)
ALB (g/L)	29.90 ± 4.45ab	36.62 ± 4.60	45.07 ± 2.31
TBIL (μmol/L)	351.92 ± 190.27ab	69.41 ± 95.43	8.00 ± 3.49
Cr (μmol/L)	95.56 ± 55.81ab	63.82 ± 11.97	65.00 ± 11.61
INR	2.01 (1.13)ab	1.13 (0.26)	0.95 (0.10)
HBeAg (positive rate, %)	14 (32.55%)	21 (48.84%)	ND
HBV-DNA (log10 copies/mL)	6.74 ± 7.35b	4.88 ± 1.99	ND
PCT (ng/mL)	0.53 (0.43)ab	0.07 (0.20)	0.02 (0.02)
IL-6 (pg/mL)	15.50 (24.00)ab	7.50 (7.00)	4.00 (4.00)
MELD	33.48 ± 4.79b	8.43 ± 7.42	ND
sMR (pg/mL)	114.94 ± 49.65ab	80.75 ± 34.45	26.51 ± 8.62

The normally distributed data are expressed as the mean ± standard deviation. The non-normally distributed data are expressed as the median (interquartile range).

^aP < 0.05 vs HCs;

^bP < 0.05 vs CHB.

HBV: Hepatitis B virus; ACLF: Acute-on-chronic liver failure; CHB: Chronic hepatitis B; HCs: Healthy controls; ALB: Albumin; PTA: Prothrombin activity; TBIL: Total bilirubin; Cr: Creatinine; INR: International normalized ratio; HBeAg: Hepatitis B e antigen; PCT: Procalcitonin; IL-6: Interleukin-6; MELD: Model for end-stage liver disease; sMR: Soluble mannose receptor; ND: Not determined.